| 1 |
Pridopidine
|
3 |
- Randomized (3:2), double-blind, placebo-controlled study followed by an open-label extension period
- Able to swallow a capsule.
- Sites in MA, NE, TX
|
Prilenia |
| 2 |
RAPA-501
|
2/3 |
- no placebo
- autologous hybrid TREG/Th2 cells delivered intravenously
- site in MA
|
Rapa Therapeutics LLC |
| 3 |
NUZ-001
|
2/3 |
- Exclusion if family history of SOD1 or VCP-associated ALS
- Matching placebo
- Site in MA
|
Merit E. Cudkowicz, MD |
| 4 |
PHENOGENE-1A (Cromolyn)
|
2 |
- Multifunctional therapy based on a repurposed drug, formulated with novel targeted delivery technology
- This approach is designed to achieve therapeutic concentrations in both blood and brain, where it acts on key mechanisms involved in neuroinflammation and neurodegeneration
- sites in CA, FL, NY
|
PhenoNet, Inc. |
| 5 |
COYA 302
|
2 |
- Combination therapy with a dual immunomodulatory mechanism of action intended to enhance the anti-inflammatory function of regulatory T cells (Tregs) and suppress the inflammation produced by activated monocytes and macrophages
- Sites in GA, MA, MO, NE, TX,
|
Coya Therapeutics |
| 6 |
Vit E, N-Ac cysteine, L-cystine, Nicotinamide, Taurursodiol
|
2 |
|
Dallas VA Medical Center |
| 7 |
ranolazine
|
2 |
- placebo controlled trial evaluating two doses of ranolazine
- sites in CA, FL, KS, OH, MO
|
Swathy Chandrashekhar, MBBS |
| 8 |
CORT113176 (dazucorilant)
|
2 |
- open-label extension (OLE) study
- less than 50% placebo
- trial sites across the globe
|
Corcept Therapeutics |
| 9 |
Tofersen
|
2 |
- phase 2 study testing tofersen (Qalsody) in non-SOD1 and non-FUS related cases of sporadic and familial ALS
- must have done genetic testing to confirm absence of SOD1 and FUS mutations
- site in MO
|
Washington University School of Medicine |
| 10 |
MTP-101C
|
1/2 |
|
Duke University |
| 11 |
VTx-002
|
1/2 |
- Vectorized antibody treatment targeting TDP-43 pathology
- Two escalating dose (low dose and high dose) cohorts are planned
- The duration of the study will be a maximum of 5 years and 5 weeks (265 weeks) for each participant
- site in MA
|
Vector Y Therapeutics |
| 12 |
prosetin
|
1 |
- placebo controlled trial lasting 14 days followed by open label extension
- oral drug designed to target MAP4 kinase
- site in MA
|
ProJenX |
| 13 |
AMX0114
|
1 |
- 25% chance of placebo
- antisense oligoneucleotide not limited to genetic ALS and designed to target calpain 2
- intrathecal delivery of up to 4 doses
- sites in CA, DC, FL, MA, MN, PA, TN, TX
|
Amylyx Pharmaceuticals Inc. |
| 14 |
INS1202
|
1 |
- no placebo
- recruiting SOD1 and Sporadic patients
- site in MO
|
Insmed Gene Therapy LLC |
| 15 |
SPG302
|
|
- Expanded Access Program for people that are not eligible for trials
- Once a day oral pill that aims to restore synapses
- Sites in AL, AZ, CA, FL, IL, MA, NH, NJ, NY, PA, VA
|
Spinogenix |
| 16 |
Psilocybin
|
Early 1 |
|
Johns Hopkins University |
| 17 |
MN-166 (ibudilast)
|
|
- Expanded Access Program for people that are not eligible for trials
- Contact WideTrial to join interest list to participate and see additional contact info here
- Site in AZ, CA, CT, FL, IN, MN, NC, TN, VA
|
Mayo Clinic |